Jin Medical lists Wang Ziqiang as director, CFO

Jin Medical International Ltd. submitted an initial insider ownership report for Wang Ziqiang.

Rhea-AI Filing Summary

Jin Medical International Ltd. submitted an initial insider ownership report for Wang Ziqiang. The filing identifies him as both a director and the company’s Chief Financial Officer. The Form 3 does not report any insider share purchases, sales, or other transactions.

Key Terms

Chief Financial Officer, director, Form 3

3 terms

Chief Financial Officer financial

"officer_title: "Chief Financial Officer""

A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.

director financial

""is_director": 1 for reporting person Wang Ziqiang"

Form 3 regulatory

"INSIDER FILING DATA (Form 3)"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Jin Medical International (ZJYL) disclose about Wang Ziqiang in this Form 3?

The filing identifies Wang Ziqiang as both a director and Chief Financial Officer of Jin Medical International Ltd. It is an initial insider ownership report and does not list any share purchases, sales, or other insider transactions for him.

Does this Jin Medical (ZJYL) Form 3 show any insider share purchases or sales?

No, the Form 3 for Jin Medical International Ltd. reports no insider share purchases, sales, or other transactions. It only records Wang Ziqiang’s status as a director and Chief Financial Officer without detailing any specific holdings or trading activity.

Who is the reporting person in Jin Medical International’s (ZJYL) Form 3 filing?

The reporting person is Wang Ziqiang. The Form 3 notes that he serves as a director and as Chief Financial Officer of Jin Medical International Ltd., but does not include any insider trading transactions or derivative positions associated with him.

What executive role does Wang Ziqiang hold at Jin Medical International (ZJYL)?

According to the Form 3, Wang Ziqiang serves as Chief Financial Officer of Jin Medical International Ltd. He is also identified as a director, making him both an executive officer and a board member in this insider disclosure.

Does the Jin Medical (ZJYL) Form 3 include any derivative or option positions for Wang Ziqiang?

No, the Form 3 does not list any derivative or option positions for Wang Ziqiang. The derivative summary is empty, and the filing focuses only on identifying him as a director and Chief Financial Officer without detailing additional financial instruments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/24/2026 - 10:42 AM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Wang Ziqiang

(Last) (First) (Middle)

C/O JIN MEDICAL INTERNATIONAL LTD.

NO. 33 LINGXIANG ROAD, WUJIN DISTRICT

(Street)

CHANGZHOU JIANGSU

(City) (State) (Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Jin Medical International Ltd. [ ZJYL ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Ziqiang Wang	04/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)